Sergio Rovner, MD
Endocrinology, Diabetes & Metabolism · El Paso, TXNPI 1437164803
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $537,298 of the $645,695 with a category attached, or 83.2%. 57 manufacturers reported payments, led by Lilly USA, LLC at 33.7% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,610 payments — averaging $247.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$217K
- Novo Nordisk$99K
- Amgen$68K
- Corcept Therapeutics$55K
- Boehringer Ingelheim$36K
- Sanofi-aventis U.S. LLC$34K
- plus $137K from 51 others
Across 631 payments — averaging $3509.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$708K
- Eli Lilly$313K
- Sanofi US Services Inc.$233K
- AstraZeneca$232K
- Boehringer Ingelheim International GmbH$229K
- Boehringer Ingelheim Pharma GmbH & Co.kg$195K
- plus $305K from 12 others
What the payments were for
- Consulting fees$24,6694%
- Speaking & faculty fees$537,29883%
- Travel & lodging$33,1835%
- Food & beverage$50,2098%
- Education$2780%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$81,380
- JARDIANCE$64,531
- Korlym$53,092
- ZEPBOUND$49,997
- Ozempic$46,408
- TEPEZZA$45,075
- TRULICITY$40,428
- Kerendia$27,197
- RYBELSUS$26,397
- FARXIGA$24,146
- Vascepa$19,955
- SOLIQUA 100/33$17,780
- Repatha$12,798
- TOUJEO$12,626
- DEXCOM G7 GSS (161)$9,575
- DEXCOM STELO GLUCOSE BIOSENSOR$9,575
- Tresiba$8,504
- INVOKANA$8,150
- Wegovy$6,782
- BYDUREON$5,766
How this compares
$645,695 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 65 | $1,637,896 |
| OzempicSemaglutide | 1,076 | $1,475,428 |
| MounjaroTirzepatide | 826 | $1,164,748 |
| TrulicityDulaglutide | 306 | $558,179 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 486 | $524,580 |
| JardianceEmpagliflozin | 344 | $389,450 |
| Xigduo XrDapaglifloz Propaned/Metformin | 312 | $306,681 |
| IsturisaOsilodrostat Phosphate | 28 | $292,292 |
| ProliaDenosumab | 166 | $290,056 |
| FarxigaDapagliflozin Propanediol | 232 | $232,345 |
| VascepaIcosapent Ethyl | 299 | $230,488 |
| KerendiaFinerenone | 184 | $176,846 |
| Tresiba Flextouch U-200Insulin Degludec | 134 | $162,677 |
| RybelsusSemaglutide | 104 | $150,776 |
| Tresiba Flextouch U-100Insulin Degludec | 172 | $120,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $217,334 | $1,722,9261,132 claims |
| Corcept TherapeuticsKorlym | $55,069 | $1,637,89665 claims |
| Novo NordiskOzempic, Rybelsus | $98,809 | $1,626,2031,180 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $36,211 | $985,942892 claims |
| Recordati_rare_diseases_inc.Isturisa | $1,257 | $292,29228 claims |
| AmgenProlia | $67,876 | $290,056166 claims |
| AstraZenecaFarxiga | $32,238 | $232,345232 claims |
| BayerKerendia | $28,944 | $176,846184 claims |
| Radius Health, Inc.Tymlos | $855 | $116,78138 claims |
| NovartisSandostatin Lar Depot | $693 | $58,43011 claims |
| Johnson & JohnsonInvokana, Invokamet | $8,504 | $31,98739 claims |
| MerckJanuvia | $2,277 | $23,83617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in El Paso
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.